Trial Profile
A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary) ; Corticosteroids
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms Liberty AD; LIBERTY AD PRE-SCHOOL
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 26 Feb 2024 Results of pooled analysis of LIBERTY AD PRESCHOOL,LIBERTY AD PEDS , LIBERTYAD ADOL , LIBERTY AD SOLO1,LIBERTYADSOLO2 reporting serum CCL17/TARC (human TARC Quantikine ELISA kit; R&D Systems) levels from patients with moderate-to-severe or severe AD, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 09 Jan 2024 Results of pre-specified subgroup analysis of data for patients aged 6 months to 5 years with severe AD at baseline, published in the Advances in Therapy
- 22 Jul 2023 Results assessing effect of dupilumab on the extent and severity of AD across various signs (erythema, edema/papulation, excoriation, lichenification) in different anatomical regions (head and neck, trunk, upper extremities, lower extremities) in patients aged 6 months to 5 years. , published in the Dermatology and Therapy.